256 related articles for article (PubMed ID: 26160843)
21. Marsdenia tenacissima extract enhances gefitinib efficacy in non-small cell lung cancer xenografts.
Han SY; Zhao W; Sun H; Zhou N; Zhou F; An G; Li PP
Phytomedicine; 2015 May; 22(5):560-7. PubMed ID: 25981922
[TBL] [Abstract][Full Text] [Related]
22. Combined treatment with Epimedium koreanum Nakai extract and gefitinib overcomes drug resistance caused by T790M mutation in non-small cell lung cancer cells.
Song J; Zhong R; Huang H; Zhang Z; Ding D; Yan H; Sun E; Jia X
Nutr Cancer; 2014; 66(4):682-9. PubMed ID: 24738693
[TBL] [Abstract][Full Text] [Related]
23. Synergistic cytotoxicity and apoptosis induced in human cholangiocarcinoma cell lines by a combined treatment with tumor necrosis factor-alpha (TNF-alpha) and triptolide.
Panichakul T; Wanun T; Reutrakul V; Sirisinha S
Asian Pac J Allergy Immunol; 2002 Sep; 20(3):167-73. PubMed ID: 12587840
[TBL] [Abstract][Full Text] [Related]
24. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
25. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
26. TAZ regulates cell proliferation and sensitivity to vitamin D3 in intrahepatic cholangiocarcinoma.
Xiao H; Tong R; Yang B; Lv Z; Du C; Peng C; Ding C; Cheng S; Zhou L; Xie H; Wu J; Zheng S
Cancer Lett; 2016 Oct; 381(2):370-9. PubMed ID: 27554639
[TBL] [Abstract][Full Text] [Related]
27. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
[TBL] [Abstract][Full Text] [Related]
28. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
29. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
30. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
[TBL] [Abstract][Full Text] [Related]
31. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
32. Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
Liu H; Li L; Li XQ; Liu XJ; Zhen YS
Anticancer Drugs; 2009 Jan; 20(1):41-9. PubMed ID: 19342999
[TBL] [Abstract][Full Text] [Related]
33. Hydroxytyrosol inhibits cholangiocarcinoma tumor growth: an in vivo and in vitro study.
Li S; Han Z; Ma Y; Song R; Pei T; Zheng T; Wang J; Xu D; Fang X; Jiang H; Liu L
Oncol Rep; 2014 Jan; 31(1):145-52. PubMed ID: 24247752
[TBL] [Abstract][Full Text] [Related]
34. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.
Choi YJ; Rho JK; Jeon BS; Choi SJ; Park SC; Lee SS; Kim HR; Kim CH; Lee JC
Cancer Chemother Pharmacol; 2010 Jul; 66(2):381-8. PubMed ID: 19921194
[TBL] [Abstract][Full Text] [Related]
35. Cryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/Akt/NFκB pathways in cholangiocarcinoma cells.
Ke F; Wang Z; Song X; Ma Q; Hu Y; Jiang L; Zhang Y; Liu Y; Zhang Y; Gong W
Drug Des Devel Ther; 2017; 11():1753-1766. PubMed ID: 28670110
[TBL] [Abstract][Full Text] [Related]
36. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
[TBL] [Abstract][Full Text] [Related]
37. Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines.
Ling S; Feng T; Ke Q; Fan N; Li L; Li Z; Dong C; Wang C; Xu F; Li Y; Wang L
Oncol Rep; 2014 Jun; 31(6):2611-8. PubMed ID: 24788596
[TBL] [Abstract][Full Text] [Related]
38. Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth.
Moriceau G; Roelofs AJ; Brion R; Redini F; Ebetion FH; Rogers MJ; Heymann D
Cancer; 2012 Feb; 118(3):750-60. PubMed ID: 21751201
[TBL] [Abstract][Full Text] [Related]
39. Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation.
Tsai CM; Chiu CH; Chang KT; Chen JT; Lai CL; Chen YM; Hsiao SY
J Thorac Oncol; 2012 Aug; 7(8):1218-27. PubMed ID: 22659964
[TBL] [Abstract][Full Text] [Related]
40. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]